135 related articles for article (PubMed ID: 9245968)
1. Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities.
Ni Y; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):724-31. PubMed ID: 9245968
[TBL] [Abstract][Full Text] [Related]
2. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
3. MnDPDP enhanced magnetic resonance imaging of focal liver lesions.
King LJ; Burkill GJ; Scurr ED; Vlavianos P; Murray-Lyons I; Healy JC
Clin Radiol; 2002 Dec; 57(12):1047-57. PubMed ID: 12475527
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study.
Wang C; Ahlström H; Ekholm S; Fagertun H; Hellström M; Hemmingsson A; Holtås S; Isberg B; Jonnson E; Lönnemark-Magnusson M; McGill S; Wallengren NO; Westman L
Acta Radiol; 1997 Jul; 38(4 Pt 2):643-9. PubMed ID: 9245958
[TBL] [Abstract][Full Text] [Related]
5. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies.
Rummeny EJ; Torres CG; Kurdziel JC; Nilsen G; Op de Beeck B; Lundby B
Acta Radiol; 1997 Jul; 38(4 Pt 2):638-42. PubMed ID: 9245957
[TBL] [Abstract][Full Text] [Related]
6. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging.
Ahlström H; Gehl HB
Acta Radiol; 1997 Jul; 38(4 Pt 2):660-4. PubMed ID: 9245961
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.
Padovani B; Lecesne R; Raffaelli C; Chevallier P; Drouillard J; Bruneton JN; Lambrechts M; Gordon P
Eur J Radiol; 1996 Nov; 23(3):205-11. PubMed ID: 9003926
[TBL] [Abstract][Full Text] [Related]
8. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings.
Kane PA; Ayton V; Walters HL; Benjamin I; Heaton ND; Williams R; Karani JB
Acta Radiol; 1997 Jul; 38(4 Pt 2):650-4. PubMed ID: 9245959
[TBL] [Abstract][Full Text] [Related]
9. Technical report: lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma.
Burkill GJ; Mannion EM; Healy JC
Clin Radiol; 2001 Jan; 56(1):67-71. PubMed ID: 11162701
[TBL] [Abstract][Full Text] [Related]
10. MnDPDP-enhanced magnetization transfer MR imaging: implications for effective liver imaging.
Halavaara J; Abo-Ramadan U; Markkola A; Aronen H; Häkkinen AM
Magn Reson Imaging; 2003 Jan; 21(1):47-50. PubMed ID: 12620545
[TBL] [Abstract][Full Text] [Related]
11. Small (Kim KW; Kim AY; Kim TK; Park SH; Kim HJ; Lee YK; Park MS; Ha HK; Kim PN; Kim JC; Lee MG
AJR Am J Roentgenol; 2004 May; 182(5):1233-40. PubMed ID: 15100125
[TBL] [Abstract][Full Text] [Related]
12. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques.
Halavaara JT; Lamminen AE
J Comput Assist Tomogr; 1997; 21(1):94-9. PubMed ID: 9022776
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution and general safety of MnDPDP in male beagle dogs, with or without total common bile duct obstruction.
Grant D; Toft KG; Martinsen I; Atzpodien E
Acta Radiol; 1997 Jul; 38(4 Pt 2):732-9. PubMed ID: 9245969
[TBL] [Abstract][Full Text] [Related]
14. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
15. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2.
Ni Y; Petré C; Bosmans H; Miao Y; Grant D; Baert AL; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):700-7. PubMed ID: 9245965
[TBL] [Abstract][Full Text] [Related]
16. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool.
Helmberger TK; Laubenberger J; Rummeny E; Jung G; Sievers K; Döhring W; Meurer K; Reiser MF
Eur Radiol; 2002 Jan; 12(1):62-70. PubMed ID: 11868075
[TBL] [Abstract][Full Text] [Related]
17. NMR relaxation studies with MnDPDP.
Southon TE; Grant D; Bjørnerud A; Moen OM; Spilling B; Martinsen I; Refsum H
Acta Radiol; 1997 Jul; 38(4 Pt 2):708-16. PubMed ID: 9245966
[TBL] [Abstract][Full Text] [Related]
18. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characterisation of mangafodipir trisodium.
Tirkkonen B; Aukrust A; Couture E; Grace D; Haile Y; Holm KM; Hope H; Larsen A; Lunde HS; Sjøgren CE
Acta Radiol; 1997 Jul; 38(4 Pt 2):780-9. PubMed ID: 9245974
[TBL] [Abstract][Full Text] [Related]
20. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis.
Bartolozzi C; Donati F; Cioni D; Crocetti L; Lencioni R
Eur Radiol; 2000; 10(11):1697-702. PubMed ID: 11097390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
